1-3 of 3
Simona Degli Esposti, MD
Close
Sort by
Journal Articles

DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) Effects on Patient-Reported Outcome (PRO) Measures in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Rakesh Popat, Sagar Lonial, MD FACP, Peter M. Voorhees, MD, Simona Degli Esposti, MD, Ira Gupta, MD, Joanna Opalinska, MD, Sandhya Sapra, PhD, Boris Gorsh, PharmD, Zangdong He, PhD, David M Kleinman, MD, Debra Schaumberg, OD, MPH, ScD, Angely Loubert, PharmD, MSc, Juliette Meunier, MSc, Antoine Regnault, PhD, Laurie Eliason, MPH
Journal: Blood
Blood (2020) 136 (Supplement 1): 27–28.
https://doi.org/10.1182/blood-2020-140013
Published: 2020
Journal Articles

Ocular Health of Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Data from the DREAMM-2 Trial of Belantamab Mafodotin (Belamaf)

Rakesh Popat, Aikaterini Kazantzi, MD, Asim Farooq, MD, Praneetha Thulasi, MD, Sagar Lonial, MD FACP, Andrzej Jakubowiak, MD PhD, Ashraf Z. Badros, MD, Bennie H. Jeng, MD, Joanna Opalinska, MD, January Baron, MS, Trisha Piontek, BSN, Julie Byrne, PhD, Lynsey Womersley, MSc, Ira Gupta, MD, Simona Degli Esposti, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 43–44.
https://doi.org/10.1182/blood-2020-139315
Published: 2020
Journal Articles

Recovery of Ocular Events with Longer-Term Follow-up in the DREAMMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Sagar Lonial, MD FACP, Ajay Nooka, MDMPH, Praneetha Thulasi, MD, Ashraf Z. Badros, MD, Bennie H. Jeng, MD, Natalie S. Callander, MD, Douglas Sborov, MD MS, Brian E. Zaugg, MD, Rakesh Popat, Simona Degli Esposti, MD, Julie Byrne, PhD, Joanna Opalinska, MD PhD, January Baron, MS, Trisha Piontek, BSN, Ira Gupta, MD, Reza Dana, MD MSc, MPH, Asim Farooq, MD, Andrzej Jakubowiak, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 26–27.
https://doi.org/10.1182/blood-2020-140078
Published: 2020